NVO Stock Recent News

NVO LATEST HEADLINES

NVO Stock News Image - prnewswire.com

NEW YORK , Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025.

prnewswire.com 2025 Aug 19
NVO Stock News Image - globenewswire.com

Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

globenewswire.com 2025 Aug 19
NVO Stock News Image - zacks.com

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.

zacks.com 2025 Aug 19
NVO Stock News Image - newsfilecorp.com

Heidelberg, Germany--(Newsfile Corp. - August 19, 2025) - BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Novo Nordisk, a leading global healthcare company headquartered in Denmark. This partnership aims to address one of the most critical challenges in modern drug development: the efficient oral delivery of therapeutic peptides.

newsfilecorp.com 2025 Aug 19
NVO Stock News Image - seekingalpha.com

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended this month. Novo Nordisk faces near-term challenges from semaglutide compounders and Eli Lilly, but the recent FDA approval for MASH and international expansion offer new growth avenues. The company's pipeline, including CagriSema, high-dose semaglutide, and next-generation candidates, positions it well for a return on the stronger growth path.

seekingalpha.com 2025 Aug 18
NVO Stock News Image - globenewswire.com

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).

globenewswire.com 2025 Aug 18
NVO Stock News Image - globenewswire.com

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.

globenewswire.com 2025 Aug 18
NVO Stock News Image - invezz.com

Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18th after Bagsværd-headquartered Novo Nordisk (NYSE: NVO) announced a GLP-1 partnership with the healthcare platform. According to the companies' joint press release today, “all strengths of Ozempic and Wegovy are now available to eligible self-paying patients for $499/month through GoodRx.

invezz.com 2025 Aug 18
NVO Stock News Image - seekingalpha.com

Novo Nordisk A/S is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels. Novo remains the global leader in diabetes and obesity drugs, with strategic U.S. manufacturing expansion. Novo's free cash flow margins could recover through 2027 as it expands its manufacturing to take on Lilly and peers.

seekingalpha.com 2025 Aug 18
NVO Stock News Image - seekingalpha.com

Novo Nordisk A/S Q2 earnings were solid, but the guidance disappointed. My investment decision was based on a long-term outlook rather than this single quarter. Novo Nordisk's narrative shifted rapidly from crisis to opportunity due to underwhelming Eli Lilly trial results and Wegovy's new FDA approval for liver disease. NVO stock now trades at a deep discount, with valuation metrics at half their historical averages, despite maintaining strong revenue growth and innovation momentum.

seekingalpha.com 2025 Aug 18
10 of 50